Exploring Genetic Targeted Therapies in R/R Acute Myeloid Leukemia (AML)

Ghayas C. Issa, MD, describes the typical presentation of patients with acute myeloid leukemia and provides clinical insights on evaluating response and potential disease progression.

An expert on acute myeloid leukemia gives an overview of disease subtypes and provides insights on risk stratification.

Ghayas C. Issa, MD, discusses the pathway between KMT2A rearrangements/NPM1 and menin in relation to leukemia cells and how these genetic abnormalities impact prognosis.

A medical oncologist reviews clinical trial data for revumenib and ziftomenib for patients with relapsed/refractory acute myeloid leukemia.

Clinical insights on the evolving treatment landscape for patients with relapsed/refractory acute myeloid leukemia, with a focus on ongoing research and unmet needs.

Ghayas C. Issa, MD, offers closing thoughts on genetic testing and targeted therapies for patients with relapsed/refractory acute myeloid leukemia.

Ghayas C. Issa, MD, gave an all-encompassing review of current treatment options for acute myeloid leukemia and what to expect in the future.